{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.74","upperLimit":"0.84","value":"0.79"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"278"}],"units":"Participants"}],"description":"Survival is defined as the minimum time from study entry to a relapse of any kind, death from any cause, or occurrence of a second malignant neoplasm. Patients without report of such events where censored at last contact. This will be used to compute event free survival (EFS).","dispersionType":"95% Confidence Interval","groups":[{"description":"Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim","id":"OG000","title":"Group 1"}],"paramType":"NUMBER","populationDescription":"Eligible (n=278). Follow-up for censored patients (n=223) is 75 months (range: 4.7 to 108 months).","reportingStatus":"POSTED","timeFrame":"At 60 months","title":"Event Free Survival (EFS)","type":"PRIMARY","unitOfMeasure":"Probability of survival"}